Navigation Links
YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS
Date:9/23/2007

ear:

- YM USA was cleared by the US FDA to expand its second-line clinical

trial in children with inoperable, recurrent, treatment-resistant

brain cancer into the US

- Oncoscience AG reported completion of patient enrolment in the

Phase III, first-line, pediatric brain cancer trial.

- Oncoscience AG reported initiation of late-stage trials in adult

glioma and pancreatic cancer.

- YM reported positive preliminary results of a Phase I/II trial of

nimotuzumab in combination with radiation for the treatment of

non-small-cell lung cancer (NSCLC).

- The first 20 patients were recruited into the Phase II colorectal

trial by the date of this release.

AeroLEF(TM):

AeroLEF(TM) is a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain. AeroLEF(TM) permits patients to identify and select the appropriate dose in real-time for each pain episode to achieve both rapid onset and extended duration of analgesia.

During Fiscal 2007:

- YM announced that AeroLEF(TM) had met the primary endpoint in its

first randomized, placebo-controlled Phase IIb trial enrolling opioid-

naive patients with post-operative pain following orthopedic surgery.

A statistically significant difference in pain relief and pain

intensity to placebo (p=0.0194) was reported.

- YM received clearance from the FDA to initiate a Phase II trial in the

US in opioid tolerant or opioid-naive patients. A successful trial

would further extend the utility and medical breadth of the product if

and when approved. Enrollment in its 50-patient trial is expected to

start in calendar Q4, 2007.

- A request to the FDA for an End-of-Phase II meeting prior to calendar

year-end 2007 to discuss Phase III trial desi
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... building materials using light, developed by researchers at the ... are often considered the realm of science fiction, such ... cloaked starships won,t be a reality for quite some ... materials with building blocks a few billionths of a ... that light flies through them, and works on large ...
(Date:7/28/2014)... , July 28, 2014 Sapphire ... technologies, today announced the appointment of biotechnology veteran ... the board of directors. Levine replaces Cynthia ,CJ, Warner, ... She will remain chairman of the company,s board of ... Sapphire Energy,s mission to deliver commercial scale algae-based fuels ...
(Date:7/28/2014)... The Workgroup for Electronic Data Interchange ... of health IT to create efficiencies in healthcare information ... Workgroup has developed an issue brief titled, “What ... The HPID Workgroup, a part of WEDI’s Strategic National ... Medicare and Medicaid Services (CMS) to identify common misuse ...
(Date:7/28/2014)... “2014 Deep Research Report ... a professional and in-depth research report on ... introduces Lubricant basic information, including Lubricant definition, ... industry overview. This research covers the international ... well as global industry analysis covering macroeconomic ...
Breaking Biology Technology:Building 'invisible' materials with light 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4
... of Integrated Global Services, CAMBRIDGE, Mass., April ... under a new name, Abt Bio-Pharma Solutions, Inc., ... company will continue to,provide custom strategic, research and ... diagnostics industries,utilizing a team approach that blends decades ...
... 1, 2008 Cardium Therapeutics,(Amex: CXM ... announced today that,InnerCool has entered into a ... a leading distributor of cardiology,medical products. Under ... have,exclusive marketing, sales and distribution rights in ...
... N.J., April 1, 2008 Derma Sciences,Inc (OTC Bulletin ... that sales for 2007 were $34.1 million, an increase ... Gross margins held steady at 34,percent, but due primarily ... the,pipeline, and expanding the Company,s marketing and sales staffs, ...
Cached Biology Technology:Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc. 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 3Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 5Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 6Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 7Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 8Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 9Derma Sciences Reports Fourth Quarter Year-End Results for 2007 2Derma Sciences Reports Fourth Quarter Year-End Results for 2007 3Derma Sciences Reports Fourth Quarter Year-End Results for 2007 4Derma Sciences Reports Fourth Quarter Year-End Results for 2007 5
(Date:7/28/2014)... About 100 drugs already approved by the U.S. Food ... prevent the growth of certain bacterial pathogens inside human ... Mediterranean spotted fever. The findings, published in mBio ... for Microbiology, demonstrate a new way of identifying non-antibiotic ... , A handful of drugs on the list ...
(Date:7/28/2014)... showing signs of damage from the Deepwater Horizon oil spill ... Gulf of Mexico. The discovery was made by a team ... University. A paper describing this work and additional impacts of ... be published during the last week of July 2014 in ... the National Academy of Sciences . , "The footprint of ...
(Date:7/28/2014)... the South Pole in 1911, but new research shows ... , Using data from 16 ice cores collected from ... South Pole, a group led by Joe McConnell of ... the most accurate and precise reconstruction to date of ... described in an article published today in the online ...
Breaking Biology News(10 mins):New route to identify drugs that can fight bacterial infections 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3
... ,This multidisciplinary conference on "Fibrous Protein Nanocomposites for Tailored ... the art in the design, synthesis and characterization of ... applications. The conference will be held in the ... situated at the crossroads of the Mediterranean Sea, exposed ...
... Alejandro Heuck at the University of Massachusetts Amherst recently ... of Health to map the molecular structure of a ... in mammalian cell walls. Once a channel ... plague (Yersinia pestis), dysentery (Shigella), food poisoning (Salmonella) and ...
... - Scientists could take greater strides toward crop improvement ... to understand the mechanisms that allow plants to adapt ... say. In a perspective for the journal ... genetics, and Ivan Baxter, a research computational biologist for ...
Cached Biology News:Fibrous Protein Nanocomposites Conference 2Fibrous Protein Nanocomposites Conference 3UMass Amherst biochemists developing tools to stop plague and other bacterial threats 2UMass Amherst biochemists developing tools to stop plague and other bacterial threats 3Adoption of advanced techniques could propel crop improvement 2
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
... 100%,S-Adenosyl Methionine 2.5%,Adenosine ... <0.1%,Cystathionine ... <0.1%,Glutathione ... Assay Range: 0.1 ug/ml to 1 mg/ml,(0.26 M to 2.6 mM) ...
Panomer 9 oligodeoxynucleotides are random primers that are labeled at the 5' end with our proprietary QSY 7 dye and they are useful for assessing microarray spot morphology, hybridization potential ...
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
Biology Products: